TENX Tenax Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:50
Aug 31
Aug 31
Author details a portfolio shift to 70/30 long/short, explicitly shorting MRNA and ABCL.
Author details a portfolio shift to 70/30 long/short, explicitly shorting MRNA and ABCL, holding longs in COGT, VERA, KOD, ABVX, and NKTR, and closing TENX after a filing-driven squeeze.
20:28
Aug 23
Aug 23
TENX falls on weak Phase 3 data.
Reports TENX dropped from $13 to $1 after weak Phase 3 data; no directional view from speaker.
LOW
13:41
Aug 23
Aug 23
Author remains bullish on ABVX as largest position but trimmed equity for options, closed IVA.
Author remains bullish on ABVX as largest position but trimmed equity for options, closed IVA, and discusses past trades without new forward calls on most names.
LOW
21:39
Aug 22
Aug 22
The author defends their biotech competition picks.
The author defends their biotech competition picks, noting CNTX and TENX went to zero but frames this as expected risk in a high-upside game, not a current position or trade call.
16:18
Aug 22
Aug 22
Author refutes claims about past picks, clarifies TENX and RGLS were competition entries not.
Author refutes claims about past picks, clarifies TENX and RGLS were competition entries not pitches, and asks the critic to stop misrepresenting his posts.
LOW
12:03
Aug 21
Aug 21
TENX double-down question without clear thesis.
Questions doubling down on TENX after GOSS funding news, without a clear commitment or rationale.
LOW
21:50
Aug 20
Aug 20
The author dismisses another user's large position in TENX as reckless.
The author dismisses another user's large position in TENX as reckless, but does not state their own position or a directional call.
LOW
13:21
Aug 17
Aug 17
Retained in portfolio despite mixed flow
Author retains the name in their portfolio, acknowledging that the recent Q2 flow data was a mixed bag.
LOW
02:38
Aug 16
Aug 16
Author details a weekly portfolio update with explicit short on LQDA.
Author details a weekly portfolio update with explicit short on LQDA, long conviction on ABVX and VERA, partial exit on IVA, and watch-level mentions for BCRX, NKTR, TENX, and CCCC.
LOW
20:53
Aug 15
Aug 15
Author regrets entering TENX unhedged, framing it as a past mistake rather than a current.
Author regrets entering TENX unhedged, framing it as a past mistake rather than a current position or forward call.
LOW
00:37
Aug 12
Aug 12
The author rhetorically dismisses a list of biotechs as failed drugmakers.
The author rhetorically dismisses a list of biotechs as failed drugmakers, but this is sarcastic criticism without a forward-looking short position or trade call.
LOW
17:11
Aug 10
Aug 10
The author defends their binary event call accuracy by listing past winners and losers.
The author defends their binary event call accuracy by listing past winners and losers, but frames it as a track record defense rather than a current position or forward call.
LOW
13:19
Aug 10
Aug 10
Author discusses position sizing for binary high-risk trades but does not state a current.
Author discusses position sizing for binary high-risk trades but does not state a current position or forward call on Tenth-X.
LOW
12:12
Aug 10
Aug 10
Premarket movers report includes Apple downgrade by Jefferies, Meta AI model launch.
Premarket movers report includes Apple downgrade by Jefferies, Meta AI model launch, and various earnings-driven moves with Morgan Stanley upgrading HP Enterprise to overweight.
11:52
Aug 10
Aug 10
Long TENX closed after Phase 3 miss
Speaker was long TENX into Phase 3 readout; trial missed primary endpoint (6MWD p=0.63, KCCQ flat) due to under-enriched patient population. Biomarker signal (NTproBNP -49%) is real but subgroup wins on a failed primary are not approvable; speaker's original thesis no longer holds.
MED
11:04
Aug 10
Aug 10
TENX phase 3 primary endpoint failed
Reports TENX phase 3 missed primary endpoint: Week 12 6MWD difference 3.5m p=0.63; positive only in low-baseline subgroup.
LOW
02:05
Aug 10
Aug 10
The author cryptically praises $TENX as the predictable pick for "real ones" without stating.
The author cryptically praises $TENX as the predictable pick for "real ones" without stating a position or forward-looking call.
LOW
01:04
Aug 10
Aug 10
TENX long into imminent binary catalyst
Long TENX into an imminent binary catalyst; author sees a low-probability but high-magnitude outcome of $30M+ as a live scenario, with resolution expected shortly, justifying holding through the event.
MED
22:30
Aug 08
Aug 08
Notes upcoming catalysts from analyst reports
Notes upcoming catalysts for the tickers based on Cowen and UBS reports, no directional view stated.
MED
16:39
Aug 07
Aug 07
Clean post-COVID trial should vindicate Levo
Buy TENX ahead of the upcoming binary readout; prior trial failure was likely noise from COVID-era walk-test confounders (remote testing, missed visits, deconditioned patients), while the new trial uses clean in-person methodology that should allow Levo's measurable hemodynamic effect to show through.
MED
14:51
Aug 07
Aug 07
Hosting doc call on upcoming binary
Author is hosting a document call regarding an upcoming binary event for the company.
LOW
19:13
Aug 06
Aug 06
Author lists three speculative longs with bullish catalysts including acquisition.
Author lists three speculative longs with bullish catalysts including acquisition and settlement upside for August.
11:44
Aug 06
Aug 06
TENX binary mispriced; safety bear case dead
Buy TENX ahead of imminent LEVEL trial readout; safety bear case is neutralized by clean REFALS/LION HEART chronic levo data (~500 pts, no mortality signal), leaving only efficacy as downside risk, while the stock is priced at ~20-25% odds of success — a mispriced binary with slightly better-than-coin-flip odds.
HIGH
11:40
Aug 05
Aug 05
Author announces an institutional-only doc call covering heart failure trial and launch topics.
Author announces an institutional-only doc call covering heart failure trial and launch topics, but expresses no directional position or trade idea.
LOW
22:36
Aug 02
Aug 02
TENX long into August catalyst, PT $65
Long TENX into a major near-term catalyst expected this month; author plans to add under $15 with a price target of $65, while acknowledging volatility risk via planned hedges.
MED
20:20
Jul 31
Jul 31
The author notes someone avoided holding TENX into August.
The author notes someone avoided holding TENX into August, implying uncertainty about the stock's near-term risk without taking a directional position.
LOW
17:22
Jul 31
Jul 31
Author announces expert calls with former Microsoft and AMD developers plus a cardiologist.
Author announces expert calls with former Microsoft and AMD developers plus a cardiologist to discuss Tenax, Cytokinetics, and Merck, but expresses no personal position or directional view.
LOW
01:40
Jul 29
Jul 29
Buy TENX ahead of August LEVEL trial topline readout.
Buy TENX ahead of August LEVEL trial topline readout; market prices ~20-25% success odds but author argues bears' safety concerns are invalidated by clean REFALS chronic oral levo data (~500 pts, 48 weeks), and levosimendan's K-ATP venodilation mechanism uniquely addresses PH-HFpEF's wedge-pressure pathology — unlike every prior failed drug — offering asymmetric +300%/-80% binary with >60% base-case success probability.
HIGH
16:52
Jul 27
Jul 27
Increased existing long position in TENX; author references detailed prior posts on expected.
Increased existing long position in TENX; author references detailed prior posts on expected results and views the recent recovery positively.
MED
00:07
Jul 27
Jul 27
Buy TENX as the speaker's top multibagger candidate for 2026.
Buy TENX as the speaker's top multibagger candidate for 2026; expects results to approach the blue-sky scenario, drawing analogy to INSM/ABVX/IMGN as the defining biotech outperformer of their respective years.
MED
About TENX Analyst Coverage
Buzzberg tracks TENX (Tenax Therapeutics, Inc.) across 5 sources. 15 bullish vs 0 bearish calls from 5 analysts. Sentiment: predominantly bullish (33%). 45 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: seedy19tron, majgeoinvesting, A May MD.